AIM · AMEX
AIM ImmunoTech Inc.
$0.17 +0.01 (+6.25%)
Company overview
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug composed of large macromolecular double-stranded ribonucleic acid molecules for treating chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for treating genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- AMEX
- Market cap
- $6.8M
- Employees
- 21
- Headquarters
- Ocala, FL
- Website
- aimimmuno.com
- CEO
- Thomas K. Equels
- Listed
- November 2, 1995
- P/E
- -0.09
- Dividend yield
- 0.00%
Company financials
- Revenue
- $94,000
- Gross profit
- -$125,000
- Operating income
- -$10.2M
- EBITDA
- -$11.6M
- Net income
- -$13.3M
- EPS
- -$1.82
- Total assets
- $8.6M
- Total debt
- $4.6M
- Gross margin
- -132.98%
- Net margin
- -14,123.40%
- Earnings yield
- -1,134.90%
No annual geographic segmentation.
Showing FY 2022
AIM
1D
AMEX
O0.16H0.17L0.16C0.16+0.00 (+2.05%)Vol289.64K
News